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我们现有的研究证实，抗人 DR5 单链抗体(aDR5ScFv)可通过与 DR5 特异性结合，











制备了 GCS-aDR5ScFv，应用扫描电镜来检测 GCS-aDR5ScFv 的外观形态，激光粒度
分析仪分析 GCS-aDR5ScFv 纳米粒的粒径大小及分布，检测其表面 Zeta 电势。常规
培养鼠肝癌 H22 细胞，通过 Celltiter blue 法检测 GCS、GCS-aDR5ScFv 对其生长抑
制作用；流式细胞术检测 GCS-aDR5ScFv 诱导肝癌 H22 细胞的凋亡率；免疫荧光 Ho
-chest33342 检测 GCS-aDR5ScFv 诱导肝癌 H22 细胞的凋亡形态变化，Western blot















接种于 KM 小鼠右腋旁建立小鼠肝癌模型，用 0.272mg/ml GCS-aDR5ScFv 隔天治疗
并测量小鼠体重及肿瘤大小，治疗两周后获取 KM 鼠肿瘤，进行 HE 染色分析其体内
抑瘤效应及毒副作用。 
结果 
通过离子凝胶法制备的 GCS-aDR5ScFv 稳定，Zeta 电势为 24.2mV，多分散指数
为 0.203。aDR5ScFv 能够特异性与 eDR5 结合，GCS-aDR5ScFv 抑制鼠肝癌 H22 细胞
生长呈时间剂量依赖性，GCS-aDR5ScFv 终浓度分别为 0.272、0.136、0.068、
0.034mg/mL100μL 时，作用肝癌 H22 细胞 4h，其生长抑制率分别为：25.2%、15.7%、
5.8%、3.2%；作用 12h 其生长抑制率分别为：38.3%、28.2%、12.6%、7.3%；作用
24h 的生长抑制率分别为：60.3%、42.2%、27.5%、13.2%。aDR5ScFv 终浓度分别为
0.272、0.136、0.068、0.034mg/mL100μL 时，作用 4h 细胞生长抑制率分别为：36.5%、
18.7%、9.2%、5.3%；作用 12h 细胞生长抑制率分别为：65.3%、50.5%、27.2%、13.2%；
24h 的生长抑制率分别为 75.2%、62.5%、32.9%、16.2%。0.136mg/mlGCS-aDR5ScFv




GCS-aDR5ScFv 组小鼠平均体重增加了 8.2g，与 PBS 组平均体重增加 2.5g 相比，差
异显著 (p<0.05)。GCS-aDR5ScFv 和 aDR5ScFv 组小鼠的肿瘤平均重量分别为 2.12g、
3.25g，与 PBS 组平均肿瘤重量 4.97g 相比，差异显著（p<0.05）。与 PBS 组平均肿瘤
体积 5.32cm3 相比，GCS-aDR5ScFv 和 aDR5ScFv 组小鼠的肿瘤平均体积分别为 2.44 
cm3、3.52 cm3，差异显著（p<0.05）。GCS-aDR5ScFv 治疗组肿瘤组织坏死明显，肿
瘤细胞之间可见较多片状坏死及淋巴细胞浸润，肿瘤周围见片状坏死区。



















1. aDR5ScFv 能够特异结合 eDR5； 
2. 通过离子凝胶法制备的 GCS-aDR5ScFv 稳定； 
3. GCS 对于肝癌细胞无毒性作用，GCS-aDR5ScFv 抑制细胞增长呈时间剂量性，
并且 GCS-aDR5ScFv 能诱导肝癌 H22 细胞凋亡，而这种诱导凋亡的机制可能与凋亡
蛋白 active-caspase8，3、BAX 的表达水平增高相关； 



















Background & objective 
Liver cancer is the most common malignancy in the world, and ranks third place in 
the cancer cause of death. Its five-year survival rate is 7 percent.It’s cause 60 million 
deaths in one year.The treatment of liver cancer is clinical surgery,chemotherapy, 
radiotherapy and chinesemedical treatment, but can not achieve a satisfactory therapeutic 
effect for treatment of advanced hepatocellular carcinoma.Immunotherapy of biological 
protein nanoparticles as a new treatment, although in clinical practice also is not mature 
enough,but it is have research prospects for cancer treatment. 
Our existing research has confirmed that anti-human DR5 single-chain antibody can  
(aDR5ScFv) specific binding of DR5,tumor cell apoptosis induced expression of DR5,and 
also has been reported that anti-human DR5 single-chain antibody no liver toxicity,but  
rapid blood clearance and inefficient local expression of functional molecules,in vitro 
degradation and sustained release.Therefore need to find a good antibody carrier to protect 
and improve the effect of drugs.Modern nanotechnology as an effective drug delivery 
systems,able to pass small molecules and biological macromolecules therapydrug,the 
chitosan bran and its derivatives in recent years become the focus of the study of 
nanoparticles loaded with protein,it has a specific structure , physical and chemical 
properties, making it very good biocompatibility, biodegradability characteristics, low 
immunogenicity and biological activity, was used as a carrier of chemical drugs,antibodies, 
proteins,peptides,and genetic drugs.To further study the function of the single-chain 
antibody to improve antibody drug effects,we prepared glycol chitosan anti-human death 
receptor 5 single-chain antibody nanoparticles,and its identification in vitro and in vivo 


















Our laboratory had constructed aDR5ScFv antibody,GCS-aDR5ScFv prepared by 
ion-gel method, using scanning electron microscope to detect the appearance of the shape 
of the GCS-aDR5ScFv,laser particle size analyzer analysis of GCS-aDR5ScFv nanoparticl- 
es particlesdiameter and particle size distribution,and detection of the surface zeta 
potential.In order to study the effect of GCS-aDR5ScFv treat for livercancer,we have been 
transplanted mice by intraperitoneal murine liver cancer cells H22 extracted liver cancer 
cells H22 inoculated in the KM mouse next to the right axilla of H22 to constructed 
model.Treatment and measurement of body weight of mice and tumor size after treated 
with GCS-aDR5ScFv (0.272mg/ml) every two days,after two weeks of treatment for KM 
mouse tumor.HE staining assay for the tumor tissue were performed to detect apoptosis.In 
vitro experiments,we cultured H22 cells and through celltitler were detected GCS, GCS- 
aDR5ScFv for H22 cytotoxic; the rate of apoptosis of hepatoma H22 cells induced by 
GCS-aDR5ScFv and detected by flow cytometry; the detection of GCS-aDR5ScFv induced 
apoptosis effect of H22 cells by immune fluorescence Hochest33342.Western blotting 
detection of the protein active-the caspase8,active-caspase3,BAX expression in vitro and in 
vivo induction apoptosis mechanisms. Application of rat liver cancer cells H22 inoculated 
in KM mice next to the right axillary establishment of a mouse liver cancer model, 
treatment with GCS-aDR5ScFv（0.272mg/ml） the next day and the measurement of body 
weight of mice and tumor size after two weeks of treatment for KM mouse tumor,HE 
staining to analyze the in vivo tumor effect and side effects. 
RESULT 
GCS-aDR5ScFv prepared by ion gel method is stable,Zeta potential and polydispersi- 
ty index were 24.2mV,0.203.From experiments show anti-human DR5 single-chain antibo- 
dy can specific binding of DR5, in vitro test can clearly,see a series of changes of apoptosis, 
Celltitler results show that GCS-aDR5ScFv inhibit the growth of H22 cells was dose and 
time dependent, A final concentration of GCS-aDR5ScFv 0.272,0.136,0.068, 0.034 mg/mL 















role 12h H22 liver cancercell growth inhibition rates were: 38.3%, 28.2%, 12.6%, 7.3%; 
24h, the growth inhibition rates were: 60.3%, 42.2%, 27.5%, 13.2%. the aDR5ScFv final 
concentration of 0.272,0.136,0.068,0.034 mg/mL100μL, the role of 4h H22 cell growth 
inhibition rates were: 36.5%, 18.7%, 9.2%, 5.3%; role in the growth of H22 cells 12h the 
inhibition rates were: 65.3%, 50.5%, 27.2%, 13.2%; 24h growth inhibition rates were 
75.2%, 62.5%, 32.9% and 16.2%. Flow cytometry tested 0.136mg/ml GCS-aDR5ScFv 
induced apoptosis of H22 cells 12h was 25.2%,immune fluorescent Hochest33342 staining 
confirm that GCS-aDR5ScFv experimental group appeared apoptosis.Western blotting 
analysis to the GCS-aDR5ScFv induced apoptosis of cells within active- caspase8,active- 
caspase3, BAX protein expression upregulated toward with control.Flow cytometry tested 
GCS- aDR5ScFv (0.136mg/ml) induced H22 cells for 12h apoptosis rate is 25.2%.  
When injectioned in the fourth day, the body weight of mice did not change 
significantly.From the administration of the fifth day to the twelfth day of GCS -aDR5ScFv 
mice on average weight gain of 8.2g, 2.5g compared with the PBS group, the average 
weight gain, significant differences (p <0.05). GCS-aDR5ScFv and the average tumor 
weight of mice aDR5ScFv respectively 2.12g, 3.25g, compared with the PBS group, the 
average tumor weight of 4.97g, significant differences (p <0.05). Compared with the PBS 
group, the average tumor volume 5.32cm3, GCS-aDR5ScFv, and aDR5ScFv mice the 
mean tumor volume of 2.44 cm3, 3.52 cm3, a significant difference (p <0.05).HE staining 
of GCS of aDR5ScFv for tumor induction of apoptosis.HE staining assay for the tumor 
tissue were performed that GCS-aDR5ScFv can induce H22 cell apoptosis.Western 
blotanalysis of GCS-aDR5ScFv treatment of tumor tissue of the active-caspase8 active- 





















1. aDR5ScFv specific binding eDR5. 
2. GCS-aDR5ScFv prepared by ion gel method is stable. 
3. Vitro experiments showed that the GCS non-toxic for the liver cancer cells, GCS- 
aDR5ScFv inhibition of cell growth was time dose dependent, and the GCS-aDR5ScFv can 
induced H22 liver cell apoptosis induced  and this mechanism may be induction of 
apoptosis with apoptotic proteinsan active-the caspase8 active-of caspase3, BAX expressio 
-n levels increased. 
4. In vivo experiments show that GCS-aDR5ScFv inhibit the growth of rat hepatoma 
cells,the inhibition mechanism may be related to the active-caspase8, active-caspase3, 
BAX protein expression. 
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